Purchase

Recombinant Human IGF-II R/IGF2R protein (rFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg3488


Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Human IGF-II R protein Gln41-Asp1365 (Accession# P11717) with a rabbit IgG Fc tag at the C-terminus.
GeneID 3482
Accession P11717
PredictedSize 172.5 kDa
SDS-PAGE 140-230 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

IGF-II R (insulin-like growth factor 2 receptor), also known as IGF2R or M6P/IGF2R, is a multifunctional type I transmembrane glycoprotein. Its primary function is to act as a "scavenger receptor," binding and internalizing ligands such as insulin-like growth factor-II (IGF-II) and lysosomal enzymes marked with mannose-6-phosphate, thereby mediating their lysosomal degradation and negatively regulating cell growth, proliferation, and metabolism. This receptor plays a crucial role in embryonic development, tumor suppression, and metabolic homeostasis. Unlike IGF1R, its cytoplasmic tail is short and lacks tyrosine kinase activity. It primarily inhibits pro-growth signals by clearing circulating IGF-II through an endocytosis-degradation pathway, functioning as a tumor-suppressive "scavenger." As a classic tumor suppressor, its gene deletion or functional inactivation is commonly observed in various cancers, leading to abnormal activation of pro-growth signaling pathways.

References:

1. Shirakawa, Jun et al. Diabetes vol. 74,12 (2025): 2351-2364. 2. Bella, Pamela et al. EMBO molecular medicine vol. 12,1 (2020): e11019. 3. Guo, Xiaorong et al. International journal of biological macromolecules vol. 284,Pt 1 (2025): 137785. 4. Han, Jie et al. Autophagy vol. 17,6 (2021): 1393-1409.


||
New chat

Able

正在加载,请稍候...